Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial

JAMA

Volumn 276, Issue 17, 1996, Pages 1409-1415

  Nathan, David M ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NDIC/DCCT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIABETES CONTROL; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; HEALTH CARE SYSTEM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTENSIVE CARE; KIDNEY FAILURE; LEG AMPUTATION; LIFESPAN; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0029908290     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.276.17.1409     Document Type: Article

References (49)

1. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, II: prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 1984;102:520-526.
2. Javitt JC, Canner JK, Sommer A. Cost-effectiveness of current approaches to the control of retinopathy in type 1 diabetics. Ophthalmology. 1989;96:255-264.
3. Andersen AR, Sandahl J, Christiansen JK, Kreiner S, Deckert T. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia. 1983;25:496-501.
4. Krolewski AS, Warram JH, Rand LI, Christler AR, Busick EJ, Kahn CR. The changing natural history of nephropathy in type 1 diabetes. Am J Med. 1985;78:785-794.
5. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic nephropathy. Diabetes. 1983; 32(suppl 2):64-78.
6. Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med. 1994;330:15-18.
7. Rubin RJ, Altrman WM, Mendelson DN. Health care expenditures for people with diabetes mellitus. J Clin Endocrinol Metab. 1994;78:809A-809F.
8. The Diabetes Control and Complications Trial Research Group. Diabetes Control and Complications Trial (DCCT) update. Diabetes Care. 1990; 13:427-433.
9. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
10. The Diabetes Control and Complications Trial Research Group. Resource utilization and costs of care in the Diabetes Control and Complications Trial. Diabetes Care. 1995;18:1468-1478.
11. @RISK: Risk Analysis and Modeling Software Version 1.12. Newfield, NY: Pallisade Corp; 1994.
12. The Diabetes Control and Complications Trial Research Group. The Diabetes Control and Complications Trial: design and methodologic considerations for the feasibility phase. Diabetes. 1986;35:530-545.
13. Orchard TJ, Dorman JS, Maser RE, et al.Prevalence of complications in IDDM by sex and duration: Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes. 1990;39:1116-1124.
14. The Diabetes Control and Complications Trial Research Group, Klein R, Moss S. A comparison of the study populations in the Diabetes Control and Complications Trial and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med. 1995;155:745-754.
15. Libman I, Songer T, LaPorte R. How many people in the U.S. have IDDM? Diabetes Care. 1993;16:841-842.
16. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Arch Ophthalmol. 1995;113:36-51.
17. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons Inc; 1980.
18. Eastman RC, Silverman R, Harris M, Javitt JC, Chiang YP, Gorden P. Lessening the burden of diabetes. Diabetes Care. 1993;16:1095-1102.
19. Javitt JC, Aiello LP, Chiang Y, Ferris PL III, Canner JK, Greenfield S. Preventive eye care in people with diabetes is cost-saving to the federal government. Diabetes Care. 1994;17:909-917.
20. Siegel JE, Krolewski AS, Warram JH, Weinstein MS. Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus. J Am Soc Nephrol. 1992;3:s111-s119.
21. Moss SE, Klein R, Klein BEK. The prevalence and incidence of lower extremity amputation in a diabetic population. Arch Intern Med. 1992;152:610-616.
22. Javitt JC, Aiello LP, Bassi LJ, Chiang YP, Canner JK. Detecting and treating retinopathy in patients with type I diabetes mellitus. Ophthalmology. 1991;10:1565-1573.
23. Chiang YP, Bassi LJ, Javitt JC. Federal budgetary costs of blindness. Milbank Q. 1992;70:319-340.
24. Renal Data System. USRDS 1993 Annual Data Report. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; March 1993:14.
25. Eckman MH, Greenfield S, Mackey WC, et al. Foot infections in diabetic patients: decision and cost-effectiveness analyses. JAMA. 1995;273:712-720.
26. Javitt JC, Chiang YP. Economic impact of diabetes. In: Harris MI, ed. Diabetes in America. 2nd ed. Washington, DC: US Government Printing Office; June 1995.
27. The Early Treatment Diabetic Study Research Group. Photocoagulation for diabetic macular edema. Arch Ophthalmol. 1985;103:1796-1806.
28. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Ophthalmology. 1981;88:583-600.
29. Ramlau-Hansen H, Bang Jespersen NC, Anderson PK, Borch-Johnsen K, Deckert T. Life insurance for insulin-independent diabetics. Scand Actuarial J. 1987:19-36.
30. Renal Data System. USRDS 1995 Annual Data Report. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; April 1995.
31. Haddix AC, Teutsch SM, Shaffer PA, Dunet DO. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation. New York, NY: Oxford University Press; 1996.
32. The Diabetes Control and Complications Trial Research Group. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care. 1995;18:261-376.
33. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 1994;17:616-623.
34. The Diabetes Control and Complications Trial Research Group. DCCT Manual of Operations. Springfield, Va: US Dept of Commerce, National Technical Information Service; 1993. Publication 93-183382.
35. Krahn MK, Gafni A. Discounting in the economic evaluation of health care interventions. Med Care. 1993;31:403-418.
36. Dasbach EJ, Fryback DG, Thornbury JR. Health utility preference differences. Med Decis Making. 1992:12:4. Abstract.
37. Lawrence WF, Grist TM, Brazy PC, Fryback DG. Magnetic resonance angiography in progressive renal failure. Am J Kidney Dis. 1995;25:701-709.
38. The Diabetes Control and Complications Trial Research Group. The effect of intensive therapy on quality of life outcomes in the Diabetes Control and Complications Trial. Diabetes Care. 1996;19:195-203.
39. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Can Med Assoc J. 1992;146:473-481.
40. Blankenship GW. Fifteen-year argon laser and xenon photocoagulation results of Bascom Palmer Eye Institute's patients participating in the Diabetic Retinopathy Study. Ophthalmology. 1991;98:125-128.
41. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy, XV: the long-term incidence of macular edema. Ophthalmology. 1995;102:7-16.
42. Warram JH, Gearin G, Laffel L, Krolewski AS. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin creatinine ratio. J Am Soc Nephrol. 1996;7:1-8.
43. Dyck PJ, Kratz KM, Karnes JL, et al. Theprevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort. Neurology. 1993;43:817-824.
44. Humphrey LL, Palumbo PJ, Butters MA, et al. The contribution of non-insulin dependent diabetes to lower-extremity amputation in the community. Arch Intern Med. 1994;154:885-892.
45. Songer TJ. Disability in diabetes. In: Harris MI, ed. Diabetes in America. 2nd ed. Washington, DC: US Government Printing Office; June 1995.
46. Koopmanschap MA,Rutten FFH. Indirect costs in economic studies: confronting the confusion. Pharmacoeconomics. 1993;4:446-454.
47. Drummond M. Cost-of-ilmess studies. Pharmacoeconomics. 1992;2:1-4.
48. Russell LB. Is Prevention Better Than Cure? Washington, DC: Brookings Institute; 1986:36.
49. US Bureau of the Census. Statistical Abstract of the United States: 1995. 115th ed. Washington, DC: US Bureau of the Census; 1995.